Therapeutic applications of PI3K inhibitors in cardiovascular diseases

Future Medicinal Chemistry

Volumn 5, Issue 4, 2013, Pages 479-492

  Ghigo, Alessandra ^a   Morello, Fulvio ^b   Perino, Alessia ^a   Hirsch, Emilio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 5 [(2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL)METHYLIDENE] 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; AZD 6482; CZC 24832; GE 21; IC 486068; IDELALISIB; NVF BEZ 235; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; TG 100 115; UNCLASSIFIED DRUG; WORTMANNIN; YM 024;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; ENDOTHELIUM CELL; HEART DISEASE; HEART MUSCLE ISCHEMIA; HYPERTENSION; IC 50; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; THROMBOSIS;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DRUG DISCOVERY; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS;

EID: 84875141045     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.11     Document Type: Review

References (102)

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002).
2. Guillermet-Guibert J, Bjorklof K, Salpekar A et al. T he p110 b isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110g. Proc. Natl Acad. Sci. USA 105(24), 8292-8297 (2008).
3. Ghigo A, Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinases in health and disease. Subcell. Biochem. 58, 183-213 (2012).
4. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3, 4, 5-trisphosphate in neutrophil responses. Biochem. J. 296 (Pt 2), 297-301 (1993).
5. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specifc inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269(7), 5241-5248 (1994).
6. Raynaud FI, Eccles S, Clarke Pa et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 67(12), 5840-5850 (2007).
7. Maira SM, Stauffer F, Brueggen J et al. Identifcation and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo anti-tumor activity. Mol. Cancer Ther. 7(7), 1851-1863 (2008).
8. Sadhu C, Masinovsky B, Dick K, Sowell CG, Staunton DE. Essential role of phosphoinositide 3-kinase d in neutrophil directional movement. J.Immunol. 170(5), 2647-2654 (2003).
9. Geng L, Tan J, Himmelfarb E et al. A specifc antagonist of the p110d catalytic component of phosphatidylinositol 3́-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res. 64(14), 4893-4899 (2004).
10. Lannutti BJ, Meadows SA, Herman SE et al. CA L-101, a p110d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2), 591-594 (2011).
11. Barber DF, Bartolome A, Hernandez C. et al. PI3Kg inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11(9), 933-935 (2005).
12. Camps M, Ruckle T, Ji H et al. Blockade of PI3Kg suppresses joint infammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11(9), 936-943 (2005).
13. Bergamini G, Bell K, Shimamura S et al. A selective inhibitor reveals PI3Kg dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 8(6), 576-582 (2012).
14. Carnevale D, Vecchione C, Mascio G et al. PI3Kg inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovasc. Res. 93(1), 200-209 (2012).
15. Jackson SP, Schoenwaelder SM, Goncalves I et al. PI 3-kinase p110b: a new target for antithrombotic therapy. Nat. Med. 11(5), 507-514 (2005).
16. Nylander S, Kull B, Bjorkman JA et al. Human target validation of phosphoinositide 3-kinase (PI3K)b: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kb inhibitor. J. Thromb. Haemost. 10 (10), 2127-2136 (2012).
17. Gilio K, Munnix IC, Mangin P et al. Non-redundant roles of phosphoinositide 3-kinase isoforms a and b in glycoprotein VI-induced platelet signaling and thrombus formation. J. Biol. Chem. 284(49), 33750-33762 (2009).
18. Knight ZA, Gonzalez B, Feldman ME et al. A pharmacological map of the PI3-K family defnes a role for p110a in insulin signaling. Cell 125(4), 733-747 (2006).
19. Doukas J, Wrasidlo W, Noronha G et al. Phosphoinositide 3-kinase g/d inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl Acad. Sci. USA 103 (52), 19866-19871 (2006).
20. Gerber HP, Mcmurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3́-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273(46), 30336-30343 (1998).
21. Gille H, Kowalski J, Yu L et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3́-kinase activation and endothelial cell migration. EMBO J. 19 (15), 4064-4073 (2000).
22. Guo D, Jia Q, Song H-Y, Warren RS, Donner DB. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain sh2 domains. J. Biol. Chem. 270(12), 6729-6733 (1995).
23. Makinen T, Veikkola T, Mustjoki S et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 20(17), 4762-4773 (2001).
24. Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98(9), 2018-2026 (1996).
25. Graupera M, Guillermet-Guibert J, Foukas LC et al. Angiogenesis selectively requires the p110 a isoform of PI3K to control endothelial cell migration. Nature 453(7195), 662-666 (2008).
26. Heller R, Chang Q, Ehrlich G et al. Overlapping and distinct roles for PI3K{b} and {g} isoforms in S1P-induced migration of human and mouse endothelial cells. Cardiovasc. Res. 80(1), 96-105 (2008).
27. Ahmad S, Hewett PW, Wang P et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ. Res. 99(7), 715-722 (2006).
28. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher Am. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399(6736), 601-605 (1999).
29. Fulton D, Gratton J-P, Mccabe TJ et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399(6736), 597-601 (1999).
30. Gallis B, Corthals Gl, Goodlett DR et al. Identifcation of fow-dependent endothelial nitric-oxide synthase phosphorylation sites by mass spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002. J. Biol. Chem. 274 (42), 30101-30108 (1999).
31. Michell BJ, Griffths JE, Mitchelhill KI et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr. Biol. 9 (15), 845-848 (1999).
32. Yuan Tl, Choi HS, Matsui A et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc. Natl Acad. Sci. USA 105(28), 9739-9744 (2008).
33. Schmid MC, Avraamides CJ, Dippold HC et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kg, a single convergent point promoting tumor infammation and progression. Cancer Cell 19(6), 715-727 (2011).
34. Chavakis E, Carmona G, Urbich C et al. Phosphatidylinositol-3-kinase-g is integral to homing functions of progenitor cells. Circ. Res. 102(8), 942-949 (2008).
35. Madeddu P, Kraenkel N, Barcelos Ls et al. Phosphoinositide 3-kinase g gene knockout impairs postischemic neovascularization and endothelial progenitor cell functions. Arterioscler. Thromb. Vasc. Biol. 28(1), 68-76 (2008).
36. Alvarez Y, Astudillo O, Jensen L et al. Selective inhibition of retinal angiogenesis by targeting PI3 kinase. PLoS ONE 4(11), e7867 (2009).
37. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phosphatidylinositol 3́-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res. 63 (13), 3585-3592 (2003).
38. Schnell CR, Stauffer FDR, Allegrini PR et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 68(16), 6598-6607 (2008).
39. Geng L, Ta n J, Himmelfarb E et al. A specifc antagonist of the p110d catalytic component of phosphatidylinositol 3-kinase, IC486068, enhances radiation-induced tumor vascular destruction. Cancer Res. 64(14), 4893-4899 (2004).
40. Chang JD, Sukhova GK, Libby P et al. Deletion of the phosphoinositide 3-kinase p110Î gene attenuates murine atherosclerosis. Proc. Natl Acad. Sci. USA 104(19), 8077-8082 (2007).
41. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold infammation and cancer at bay. Pharmacol. Ther. 118(2), 192-205 (2008).
42. Harvey EJ, Li N, Ramji DP. Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-{g}-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(4), 806-812 (2007).
43. Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J. Immunol. 181(2), 1288-1298 (2008).
44. Wang SE, Xiang B, Guix M et al. Transforming growth factor {b} Engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol. Cell. Biol. 28(18), 5605-5620 (2008).
45. Condliffe AM, Davidson K, Anderson KE et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (4), 1432-1440 (2005).
46. Hirsch E, Katanaev VL, Garlanda C et al. Central role for G protein-coupled phosphoinositide 3-kinase g in infammation. Science 287(5455), 1049-1053 (2000).
47. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, Wu D. Roles of PLC-2 and-3 and PI3K in Chemoattractant-Mediated Signal Transduction. Science 287(5455), 1046-1049 (2000).
48. Sasaki T, Irie-Sasaki J, Jones RG et al. Function of PI3Kg in thymocyte development, T cell activation, and neutrophil migration. Science 287(5455), 1040-1046 (2000).
49. Fougerat A, Gayral S, Gourdy P et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-g reduces atherosclerosis and favors plaque stability by modulating infammatory processes. Circulation 117(10), 1310-1317 (2008).
50. Yum H-K, Arcaroli J, Kupfner J et al. Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury. J. Immunol. 167(11), 6601-6608 (2001).
51. Ruckle T, Schwarz MK, Rommel C. PI3Kg inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discov. 5(11), 903-918 (2006).
52. Fukao T, Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 24(7), 358-363 (2003).
53. Anzinger JJ, Chang J, Xu Q et al. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kg-dependent fuid-phase pinocytosis of native LDL. J. Lipid Res. 53(1), 34-42 (2012).
54. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler. Thromb. Vasc. Biol. 30(12), 2341-2349 (2010).
55. Kasirer-Friede A, Cozzi MR, Mazzucato M, De Marco L, Ruggeri ZM, Shattil SJ. Signaling through GP Ib-IX-V activates {a} IIb{b}3 independently of other receptors. Blood 103(9), 3403-3411 (2004).
56. Yap CL, Anderson KE, Hughan SC, Dopheide SM, Salem HH, Jackson SP. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin a IIbb 3. Blood 99(1), 151-158 (2002).
57. Canobbio I, Stefanini L, Cipolla L et al. Genetic evidence for a predominant role of PI3Kb catalytic activity in ITAM-And integrin-mediated signaling in platelets. Blood 114(10), 2193-2196 (2009).
58. Martin V, Guillermet-Guibert J, Chicanne G et al. Deletion of the p110b isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 115(10), 2008-2013 (2010).
59. Consonni A, Cipolla L, Guidetti G et al. Role and regulation of phosphatidylinositol 3-kinase b in platelet integrin a2b1 signaling. Blood 119(3), 847-856 (2012).
60. Kim S, Mangin P, Dangelmaier C et al. Role of phosphoinositide 3-kinase b in glycoprotein VI-mediated Akt activation in platelets. J. Biol. Chem. 284(49), 33763-33772 (2009).
61. Schiffrin El. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 59(2), 367-374 (2012).
62. Budzyn K, Marley PD, Sobey CG. Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. J. Pharmacol. Exp. Ther. 313 (3), 1248-1253 (2005).
63. Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ. Res. 83(3), 334-341 (1998).
64. Zeng G, Nystrom FH, Ravichandran LV et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101(13), 1539-1545 (2000).
65. 2+) channels. Circ. Res. 89(8), 692-699 (2001).
66. Quignard JF, Mironneau J, Carricaburu V et al. Phosphoinositide 3-kinase g mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J. Biol. Chem. 276(35), 32545-32551 (2001).
67. Vecchione C, Patrucco E, Marino G et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kg. J. Exp. Med. 201(8), 1217-1228 (2005).
68. Fernandez-Hernando C, Jozsef L, Jenkins D, Di Lorenzo A, Sessa WC. Absence of Akt1 reduces vascular smooth muscle cell migration and survival and induces features of plaque vulnerability and cardiac dysfunction during atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29(12), 2033-2040 (2009).
69. Northcott CA, Hayfick JS, Watts SW. PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110d the culprit? Hypertension 43(4), 885-890 (2004).
70. Northcott CA, Poy MN, Najjar SM, Watts SW. Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ. Res. 91(4), 360-369 (2002).
71. Zhang L, Xie P, Wang J et al. Impaired peroxisome proliferator-Activated receptor-g contributes to phenotypic modulation of vascular smooth muscle cells during hypertension. J. Biol. Chem. 285 (18), 13666-13677 (2010).
72. 2+]e enhances arterial spontaneous tone via phosphatidylinositol 3-kinase in DOCA-salt hypertension. Hypertension 43(1), 125-129 (2004).
73. Wain LV, Verwoert GC, O'reilly PF et al. Genome-wide association study identifes six new loci infuencing pulse pressure and mean arterial pressure. Nat. Genet. 43 (10), 1005-1011 (2011).
74. 2+-dependent activation of phosphoinositide 3-kinase class IIa isoform-Rho axis in blood vessels of spontaneously hypertensive rats. Hypertension 56(5), 934-941 (2010).
75. Crackower MA, Oudit GY, Kozieradzki I et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110(6), 737-749 (2002).
76. Mcmullen JR, Shioi T, Zhang L et al. Phosphoinositide 3-kinase(p110a) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100 (21), 12355-12360 (2003).
77. Shioi T, Kang PM, Douglas PS et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19(11), 2537-2548 (2000).
78. Weeks Kl, Gao X, Du X-J et al. Phosphoinositide 3-kinase p110a is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5(4), 523-534 (2012).
79. Lin RC, Weeks KL, Gao XM et al. PI3K(p110 a) protects against myocardial infarction-induced heart failure: identifcation of PI3K-regulated miRNA and mRNA. Arterioscler. Thromb. Vasc. Biol. 30(4), 724-732 (2010).
80. Mcmullen JR, Amirahmadi F, Woodcock EA et al. Protective effects of exercise and phosphoinositide 3-kinase(p110a) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104 (2), 612-617 (2007).
81. Pretorius L, Du XJ, Woodcock EA et al. Reduced phosphoinositide 3-kinase (p110a) activation increases the susceptibility to atrial fbrillation. Am. J. Pathol. 175(3), 998-1009 (2009).
82. Waardenberg AJ, Bernardo BC, Ng DC et al. Phosphoinositide 3-kinase (PI3K(p110a)) directly regulates key components of the Z-disc and cardiac structure. J. Biol. Chem. 286(35), 30837-30846 (2011).
83. 2+ channels in mediating the complex actions of angiotensin II on mouse cardiac contractility. Hypertension 56(3), 422-429 (2010).
84. Lu Z, Jiang Y-P, Wang W et al. Loss of cardiac phosphoinositide 3-kinase p110{a} results in contractile dysfunction. Circulation 120(4), 318-325 (2009).
85. 2+ currents via increased PI3Ka/PKB signaling. Circ. Res. 98(11), 1390-1397 (2006).
86. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng Y-T. Temporally controlled overexpression of cardiac-specifc PI3Ka induces enhanced myocardial contractility-A new transgenic model. Am. J. Physiol. Heart Circ. Physiol. 295(4), H1690-H1694 (2008).
87. Wu CY, Jia Z, Wang W et al. PI3Ks maintain the structural integrity of T-tubules in cardiac myocytes. PLoS ONE 6(9), e24404 (2011).
88. Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A. Twice upon a time: PI3K's secret double life exposed. Trends Biochem. Sci. 34(5), 244-248 (2009).
89. Patrucco E, Notte A, Barberis L et al. PI3Kg modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 118(3), 375-387 (2004).
90. Perino A, Ghigo A, Ferrero E et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110g. Mol. Cell 42(1), 84-95 (2011).
91. Perino A, Ghigo A, Scott JD, Hirsch E. Anchoring proteins as regulators of signaling pathways. Circ. Res. 111(4), 482-492 (2012).
92. Ghigo A, Perino A, Mehel H et al. Phosphoinositide 3-kinase g protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 126(17), 2073-2083 (2012).
93. Damilano F, Franco I, Perrino C et al. Distinct effects of leukocyte and cardiac phosphoinositide 3-kinase {g} activity in pressure overload-induced cardiac failure. Circulation 123(4), 391-399 (2011).
94. Naga Prasad SV, Barak LS, Rapacciuolo A, Caron MG, Rockman HA. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by b-Adrenergic receptor kinase 1. A role in receptor sequestration. J. Biol. Chem. 276(22), 18953-18959 (2001).
95. Naga Prasad SV, Laporte SA, Chamberlain D, Caron MG, Barak L, Rockman HA. Phosphoinositide 3-kinase regulates b2-Adrenergic receptor endocytosis by AP-2 recruitment to the receptor/b-Arrestin complex. J. Cell Biol. 158(3), 563-575 (2002).
96. Nienaber JJ, Tachibana H, Naga Prasad SV et al. Inhibition of receptor-localized PI3K preserves cardiac b-Adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112 (7), 1067-1079 (2003).
97. Perrino C, Naga Prasad SV, Schroder JN, Hata JA, Milano C, Rockman HA. Restoration of b-Adrenergic receptor signaling and contractile function in heart failure by disruption of the bARK1/phosphoinositide 3-kinase complex. Circulation 111(20), 2579-2587 (2005).
98. Jin K, Song LF, He CM, Wang ZL, Hu XH, Wu XH. Intervention effect of PI3Kgamma inhibitor AS605240 on autoimmune myocarditis in mice. Sichuan Da Xue Xue Bao Yi Xue Ban 40(5), 817-820, 825 (2009).
99. Siragusa M, Katare R, Meloni M et al. Involvement of phosphoinositide 3-kinase g in angiogenesis and healing of experimental myocardial infarction in mice. Circ. Res. 106(4), 757-768 (2010).
100. Ban K, Cooper AJ, Samuel S et al. Phosphatidylinositol 3-kinase g is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ. Res. 103(6), 643-653 (2008).
101. Haubner BJ, Neely GG, Voelkl JGJ et al. PI3Kg protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS ONE 5(2), e9350 (2010).
102. Curcio A, Noma T, Naga Prasad SV et al. Competitive displacement of phosphoinositide 3-kinase from b-Adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. Am. J. Physiol. Heart Circ. Physiol. 291(4), H1754-H1760 (2006).